Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 2004;90:1119-1123; doi:10.1136/hrt.2003.028167
Copyright © 2004 BMJ Publishing Group Ltd & British Cardiovascular Society
Heart 2004;90:1119-1123
© 2004 by BMJ Publishing Group & British Cardiac Society

CARDIOVASCULAR MEDICINE

Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia

R R T Castro1,*, G Porphirio2,{dagger}, S M Serra2,{dagger} and A C L Nóbrega1,*

1 Department of Physiology and Pharmacology, Universidade Federal Fluminense, Niterói, Brazil
2 Post-Graduate Program in Cardiology, Universidade Federal Fluminense, Niterói, Brazil

Correspondence to:
Correspondence to:
Dr A C L Nóbrega
Rua Cinco de Julho, 318/1001, Niterói, RJ 24220-111, Brazil; anobrega{at}urbi.com.br

Objective: To determine the acute effects of pyridostigmine bromide, a reversible cholinesterase inhibitor, during exercise in patients with coronary artery disease.

Design: Double blind, randomised, placebo controlled, crossover study.

Setting: Outpatients evaluated in an exercise test laboratory.

Patients: 15 patients with exercise induced myocardial ischaemia.

Interventions: Maximal cardiopulmonary exercise test on a treadmill according to an individualised ramp protocol on three days. The first day was used for adaptation to the equipment and to determine exercise tolerance and the presence of exercise induced ischaemia. On the other two days, the cardiopulmonary exercise test was performed two hours after oral administration of pyridostigmine (45 mg) or placebo. All patients were taking their usual medication during the experiments.

Main outcome measures: Rate–pressure product and oxygen uptake during exercise.

Results: Pyridostigmine inhibited the submaximum chronotropic response (p = 0.001), delaying the onset of myocardial ischaemia, which occurred at a similar rate–pressure product (mean (SE) placebo 20.55 (1.08) mm Hg x beats/min 103; pyridostigmine 19.75 (1.28) mm Hg x beats/min 103; p = 0.27) but at a higher exercise intensity (oxygen consumption: placebo 18.6 (1.7) ml/kg/min; pyridostigmine 19.6 (1.8) ml/kg/min; p = 0.03). Also, pyridostigmine increased peak oxygen consumption (placebo 23.6 (2) ml/kg/min; pyridostigmine 24.8 (2) ml/kg/min; p = 0.01) and peak oxygen pulse (placebo 12.9 (1) ml/beat; pyridostigmine 13.6 (1) ml/beat; p = 0.02).

Conclusions: Pyridostigmine improved peak exercise tolerance and inhibited the chronotropic response to submaximum exercise, increasing the intensity at which myocardial ischaemia occurred. These results suggest that pyridostigmine can protect against exercise induced myocardial ischaemia.

Abbreviations: V·CO2, carbon dioxide production; V·E, minute ventilation; V·O2, oxygen consumption

Keywords: pyridostigmine; autonomic nervous system; stable angina; exercise test; maximum oxygen consumption


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.